Lung cancer shows diverse histological subtypes. Largecell neuroendocrine cell carcinoma and small-cell lung carcinoma show similar histological features and clinical behaviors, and can be classified as high-grade neuroendocrine carcinoma (HGNEC) of the lung. Here we elucidated the molecular classification of pulmonary endocrine tumors by copy-number profiling. We compared alterations of copy number with the clinical outcome of HGNEC and identified a chromosomal gain of the DEK oncogene locus (6p22.3) that was significantly associated with poor prognosis. We further confirmed that DEK overexpression was associated with poor prognosis in a larger set of HGNEC. Downregulation of DEK by small hairpin RNA led to a marked reduction of in vitro colony formation, in vivo tumorigenicity and chemo-resistance, and was associated with loss of lung cancer stem cell markers. Gene expression profiling revealed that DEK downregulation was associated with altered expression of transcriptional regulators, which specifically include known targets of interchromosomal translocations in hematopoietic tumors, and knockdown of these epigenetic modifiers affected colony formation activity. Our study showed that DEK overexpression, partly through an increase in its gene dose, mediates the activity of global transcriptional regulators and is associated with tumor initiation activity and poor prognosis in HGNEC.
Introduction
Lung cancer is one of the most prevalent cancers worldwide, and shows diverse histological subtypes, including adenocarcinoma, squamous cell carcinoma, large-cell carcinoma, large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC; Travis and Brambilla, 2004) . The latter two share common histological features such as neuroendocrine differentiation and belong to a spectrum of endocrine neoplasms of the lung, which include benign (typical carcinoid; TC), intermediately malignant (atypical carcinoid; AC) and highly malignant (LCNEC and SCLC) tumors (Travis et al., 1991; Travis and Brambilla, 2004 ). LCNEC and SCLC show similar clinical behavior and can be classified as high-grade neuroendocrine carcinoma (HGNEC; Asamura et al., 2006) . Genome-wide expression profiling has supported this classification, and led to the division of HGNEC into groups showing better and poor prognosis, showing no correlation with histological subtype (LCNEC or SCLC; Jones et al., 2004) . However, details of the molecular alterations in HGNEC, especially those associated with malignant phenotypes, remain largely unknown.
Recently, many studies have reported that a selfrenewing population of cancer cells, known as cancer stem cell (CSC) or tumor-initiating cell, is responsible for histological heterogeneity, tumor recurrence, organ metastasis and drug resistance, which are hallmarks of malignancy and related to poor prognosis (Visvader and Lindeman, 2008) . Interestingly, HGNEC is well known to frequently coexist with other histological subtypes such as adenocarcinoma or squamous cell carcinoma (so-called combined tumor; Travis and Brambilla, 2004) , suggesting that this tumor contains a pluripotent stem cell-like population. Although several putative markers for lung cancer stem cells (such as CD133 and ALDH1A) have been proposed (Peacock and Watkins, 2008) , the molecular mechanisms responsible for maintaining these stem cell features are largely unknown.
To further understand the molecular mechanisms related to the progression of HGNEC, we have compared copy-number alterations with clinical outcome of HGNEC and shown that chromosomal gain of the DEK gene locus is significantly associated with poor prognosis. DEK was originally identified as a fusion partner of t(6;9)(p23;q34) translocation in a subtype of acute myeloid leukemia; von Lindern et al., 1992) and is overexpressed in several types of solid tumor such as liver cancer (Kondoh et al., 1999; Carro et al., 2006; Khodadoust et al., 2009) .
Results

Molecular classification of endocrine tumors of the lung
To clarify the chromosomal alteration profile of the endocrine tumors of the lung, we performed array-based comparative genomic hybridization (CGH) analysis of the 49 primary tumors (11 cases of TC, 2 cases of AC, 8 cases of SCLC and 28 cases of LCNEC), which include samples analyzed in our previous report (Peng et al., 2005) . We then conducted unsupervised cluster analysis of the CGH data to examine whether histological subtypes have any association with genomic classification ( Figure 1a ). As shown in Figures 1a and b , chromosome alterations in TC and AC are characteristic and clearly distinct from those observed in HGNEC (LCNEC and SCLC; distinctive bacterial artificial chromosome (BAC) clones between carcinoid and HGNEC are listed in the Supplementary Table 1) .
Thus, the copy number-based classification elucidated a carcinoid subgroup, which contains all carcinoid samples and exceptionally one LCNEC case (Carcinoid branch in Figure 1b ). Unsupervised classification revealed three subclasses (HGNEC-BR1-3) in the HGNEC group, suggesting of the possibility of molecular subtypes in HGNEC, and SCLC was significantly segregated in HGNEC-BR1 (P ¼ 0.00246). We then performed extensive molecular characterization of the lung endocrine tumors by the immunohistochemical analysis of candidate tumor suppressor (p53, PTEN and RB) and oncogene (SKP2, EGFR, MET and KIT) products in this cohort (Figure 1b) . Aberrant expressions of these proteins were more frequent in HGNEC, but no significant correlation was observed among HGNEC-branches and oncoprotein expressions (data not shown). Notwithstanding the inability to characterize this classification by known molecular markers, when clinical outcome was compared, patients in HGNEC-BR2 showed a significantly better outcome than the others (HGNEC-BR1/3; Figure 1c and Supplementary Figure 1) , suggesting of novel molecular markers that can discriminate the two groups. Then we searched for the genetic differences between HGNEC-BR1/3 (poor prognosis) and HGNEC-BR2 (good prognosis) and found that copy number alterations at four loci (12q13 EPS8 (adjusted P ¼ 0.0033), 6p22.3 DEK (P ¼ 0.017), 2p24 NBAS (P ¼ 0.022) and 2q31.3 ITGA4 (P ¼ 0.046)) differed significantly between the DEK oncoprotein in pulmonary endocrine carcinoma T Shibata et al two groups. In this study, we focused on the DEK gene because it encodes a well-known leukemia oncoprotein. Analysis of other targets (EPS8 encoding an epidermal growth factor receptor pathway substrate, and NBAS encoding a neuroblastoma amplified gene and also a fusion partner in acute myeloid leukemia (Fujita et al., 2009) ) will be reported separately. We validated the array CGH data for the DEK gene by quantitative PCR (Pearson's correlation P ¼ 0.84, Supplementary Figure  2 ). As shown in Figure 1d , the copy number of the DEK gene was significantly higher in tumors in the HGNEC-BR1/3 than in those in HGNEC-BR2. Figure 2c ) and those showing equal or weak DEK expression (DEK-low, Figure 2d ). On the basis of this criterion, we found that patients with DEK-high tumors (35/79, 44.3% of the total) showed significantly shorter survival rate than those with DEK-low tumors ( Figure 2e ). Thus, DEK expression seemed to be a marker of prognosis in HGNEC. Interestingly, DEK was expressed diffusely in DEK-high tumors, and we were unable to discern any characteristic pattern of DEK expression such as that around small vessels, which has been suggested to represent a CSC niche in neural tumors (Calabrese et al., 2007) , or a scattered pattern within the tumor (Figures 2a and c) .
Downregulation of DEK expression in SCLC reduces cell proliferation and migration activity in vitro We examined DEK expression in SCLC cell lines and found that a fraction of SCLC cell lines clearly showed DEK protein expression (Figure 2f , Supplementary  Figure 2 ). To further elucidate the functions of DEK overexpression, we transiently transfected an small hairpin RNA vector targeting the DEK gene into SBC3 and SBC5 cells to knock down DEK expression, both of which are adhesive and show moderate expression of DEK protein ( Figure 3a ). As shown in Figure 3b , we observed that transient knockdown of DEK expression decreased SCLC cell proliferation at the prolonged time (after day 2 point, similar result was observed in N230, a floating SCLC cell line, whereas no growth inhibition was observed in H69 cells, Supplementary Figure 3 and data not shown). Then we established two independent stable clones (DEKKD-1 and 2) from SBC3 in which DEK expression was considerably reduced in comparison with the clone transfected with the mock vector ( Figure 3c ). No DEKdownregulated clones were obtained from SBC5 cells. Similarly in the transient knock down experiments, we detected a modest reduction of cell proliferation in DEK-silenced clones at day 3 and a gradual increase of reduction (about 60% of the control at day 6 point; Figure 3d ). DEK-silenced clones showed a slight decrease in the S-phase fraction and increase in G2/M fraction. There was no increase of the apoptotic fraction (Figure 3f ), and there was a significant difference in cell motility between DEK-silenced and control clones ( Figure 3g ). As these features suggested a cellular senescence-like phenotype, we examined senescence-associated b-galactosidase expression in these clones. However, we found that DEK-silencing very rarely induced senescence-associated b-galactosidase positive cells (Supplementary Figure 5) .
Reduction of DEK expression robustly decreases in vitro colony formation, in vivo tumorigenicity, chemotherapyresistance and expression of stem cell markers We then performed a replating colony assay to determine the effect of DEK expression silencing on in vitro colony-forming activity. DEK-silenced clones showed a marked reduction in the number of colonies compared with the control, suggesting that DEK activity had a role in tumorigenicity of this cell line ( Figure 4a ). To further test this possibility, we transplanted these clones in immunodeficient mice. Despite of moderate decrease in in vitro cell proliferation, DEKsilenced clones rarely formed tumors (0/8 and 1/8) in vivo compared with the parent cells and the control clone (8/8 and 8/8; Figure 4b ). We also tested whether DEK downregulation has any association with chemotherapy resistance. We compared sensitivity with two anticancer drugs that are routinely used for treatment of lung cancer, cisplatin and etoposide, between DEKsilenced clones and control. Etoposide was recently identified as a selective growth inhibitor of mammary stem/progenitor cells (Gupta et al., 2009) . As in Figure 4c , DEK silencing significantly increased sensitivity to etoposide whereas no significant difference was observed in cisplatin treatment (Supplementary Figure 6 ). These observations prompted us to evaluate the expression of putative lung CSC markers, as CSC has been reported to have an important role in the efficiency of in vivo tumor formation and drug resistance. Fluorescence-activated cell sorting analysis revealed that SBC3 cells did not express CD133 antigen (Supplementary Figure 7) . We also measured Aldh1a1 expression by quantitative reverse transcriptase PCR and found that it was significantly decreased in DEKsilenced clones (Figure 4d ). Furthermore, we examined other stem cell-related molecules (Ascl1, Pou5f1 (also known as Oct-3/4), Sox2, Foxo15 and Klf4), and found that Ascl1, Pou5f1 and its direct target Fbxo15 were specifically downregulated in DEK-silenced clones ( Figure 4d and Supplementary Figure 8 ).
DEK maintains expression of transcriptional modifiers that are associated with hematological tumors
To further understand the global molecular mechanism through which DEK regulates the tumorigenicity, we compared the genome-wide expression of DEK-silenced and control clones. Gene ontology analysis revealed that the top-ranking molecular pathways altered in DEK-silenced clones were sterol/lipid metabolism (P ¼ 6.12 Â 10 À7 ) and nucleosome/chromatin assembly (P ¼ 3.66 Â 10 À6 ; Table 1 ). Genes that showed a significant difference in expression between DEK-silenced and control clones are shown in Table 2 and Supplementary Table 2 . Among them, we noticed that the expression of a large set of transcriptional regulators (such as polycomb complex component, histone modifier and DNA methyltransferase) and transcriptional factors (especially homeobox and helix-loop-helix types) were altered by DEK silencing. We further validated changes in the expression of these genes by quantitative reverse transcriptase PCR analysis (Figure 5a ). Interestingly they included many leukemic translocation target genes, which may be related to the epigenetic maintenance of stem cell features (Table 2 ). DEK-associated epigenetic modifier regulates colony formation activity and lung CSC marker expression To determine whether DEK-regulated epigenetic modifiers are directly implicated in tumor formation activity, we selected three candidates (TET1, MLLT3 and TAL1) and knocked down the expression of them using siRNA (Supplementary Figure 9) . We observed that the decreased expression of either of them significantly reduced the replating colony formation activity of SBC3 cells although it showed little effect on cell proliferation (Figure 5b and Supplementary Figure 9 ). Moreover downregulation of these DEK-targets also reduced the expression of lung CSC markers (Aldh1a1, Ascl1 and Pou5f1; Figure 5c ). Among these candidates, we then focused on MLLT3 and found that it is frequently overexpressed (35/44, 79.5%) and scattered in the nucleus of HGNEC cells (Figure 5d ). To test whether MLLT3 has any collaborative role with DEK, we examined the interaction between the two molecules. We found that MLLT3 coimmunoprecipitated with DEK ( Figure 5e and Supplementary Figure 10) and further determined the colocalization of MLLT3 and DEK proteins in SBC3 cells (Figure 5f ).
Discussion
Molecular classification of pulmonary endocrine tumors
In this study, we confirmed that the genetic changes in TC/AC were quite different from those of HGNEC on the basis of the copy number signature, as previous studies had suggested (Walch et al., 1998; D'Adda et al., 2005) . Our cluster analysis has revealed that only one LCNEC case shared a quite similar genetic profile with carcinoid tumors, suggesting that malignant progression of carcinoid occurs infrequently. Contrary to the carcinoid tumor, SCLC and LCNEC showed relatively indiscernible copy number profiles, supporting the idea that both tumors follow the relatively similar molecular carcinogenesis (Jones et al., 2004; Asamura et al., 2006) . Unsupervised classification based on the copy number alterations showed a subtype of HGNEC with a better prognosis, suggesting the existence of molecular subtypes with clinical significance in HGNEC, but this observation should be validated in a further validation set. Multiple alterations in tumor suppressors and oncogenes have been reported (Sattler and Salgia, 2003; Righi et al., 2007) , however, no prognostic DEK oncoprotein in pulmonary endocrine carcinoma T Shibata et al biomarker has been currently reported in HGNEC and our study has also failed to correlate our molecular classification with known oncoproteins. Therefore we further extracted specific loci that were associated with the prognostic classification to identify a novel diagnostic biomarker. We focused on one of the targets, the DEK gene, and quantitative copy number analyses confirmed that the increased DEK gene dose was significantly associated with poor prognosis. Several previous studies have reported that increased DEK expression is associated with malignant features in liver and colon cancers and melanoma (Kondoh et al., 1999; Han et al., 2009; Khodadoust et al., 2009) . Although it has been reported that HGNEC has a very poor clinical outcome (Asamura et al., 2006; Gustafsson et al., 2008) , previous studies have suggested the existence of subgroups that differ in their clinical courses (Jones et al., 2004) . Consistent with the genetic and functional data, we confirmed that DEK overexpression was significantly associated with a shorter time to recurrence in a large set of clinical samples.
DEK is a putative oncoprotein associated with tumor-initiating activity and regulates the transcriptional modifiers expression DEK encodes a nuclear protein that has been reported to exhibit a wide range of nuclear function; it modifies the topological conformation of DNA at replication or transcription (Alexiadis et al., 2000; Gamble and Fisher, 2007) , affects histone acetylation and the RNA splicing machinery (Ko et al., 2006; Soares et al., 2006) , positively and negatively regulates transcription (Fu et al., 1997; Campillos et al., 2003; Sammons et al., 2006) , and is implicated in DNA damage response (Kappes et al., 2008) . DEK expression is regulated by E2F and overexpression of DEK protein has been reported in several types of solid tumor (Carro et al., 2006). Moreover, DEK inhibits apoptosis by modulating p53 activity and is implicated in cellular senescence/ immortalization (Wise-Draper et al., 2006; Scoumanne and Chen, 2007) . It has been reported that DEK has transforming activity in human keratinocytes when working in association with HPV E6/E7 viral oncoproteins or p16 silencing (Wise-Draper et al., 2005 , 2009a . A large-scale resequence project of cancer genome has revealed a heterozygous missense mutation (K348N) of DEK in a case of renal tumor (http://www.sanger.ac.uk/ perl/genetics/CGP/cosmic?action ¼ sample;id ¼ 948640). Thus, DEK itself can function as an oncoprotein in solid tumors. In this study, we detected frequent gain and amplification of the DEK gene in a subset of HGNEC with poor prognosis. Delayed and moderate decrease of cell proliferation and marked reduction of in vitro colony formation activity were observed when DEK was silenced in SCLC cell lines. However, no significant increase of apoptosis or senescence was detected in contrast to previous reports of other cell types, whereas p53 expression was induced in SBC3 cells (Supplementary Figure 4 , Wise-Draper et al., 2006 , 2009a Khodadoust et al., 2009 ). This might be because both the RB and p53 pathways are frequently inactivated and could partly complement DEK-mediated anti-apoptotic and anti-senescence function in SCLC cell lines. Moreover, we have revealed that DEK has an important role in maintaining the tumorigenicity of SCLC cell lines in vivo, again supporting the possibility that DEK functions as an oncoprotein in HGNEC, whereas complementary proof by DEK overexpression could not be obtained because of the low transfection efficiency in SCLC cell lines (data not shown).
As the major phenotypes associated with DEK downregulation are in vivo tumor formation, chemotherapy-resistance and poor prognosis, we hypothesized that DEK has a role in tumor-initiating or CSC activity. A basic helix-loop-helix-type transcriptional factor, achaete-scute complex homologue 1, has been shown to regulate the tumor-initiating activity of SCLC ), and we found that the expression of lung CSC markers (Aldh1a1 and Ascl1) and putative embryonic stem cell and somatic reprogramming master regulators (Pou5f1/Oct4 and its direct target Fbxo15; Tokuzawa et al., 2003; Okita et al., 2007) were downregulated by silencing of DEK in SCLC cell lines, supporting the contention that DEK maintains CSC features in HGNEC. As it has been shown that Notch signaling has a role in maintenance of neural stem cell and also in SCLC (Sriuranpong et al., 2001; Mizutani et al., 2007) , and we detected altered expression of several Notch signal-associated genes (Table 2) by DEK downregulation, we examined activation of Notch signaling in DEK-silenced clones. However, we did not observe any significant change in CBF1-dependent transcriptional activity, which is activated by Notch signaling (Hsieh et al., 1997, Supplementary Figure 11) . To elucidate the molecular roles of DEK in these phenotypes, we conducted expression-profiling analysis. On the basis of genome-wide expression analysis, we found that DEK regulates transcriptional regulators, such as the trithorax complex (MLLT2 and MLLT3), histone acetyltransferase (MYST4), de novo DNA methyltransferase and methyl-DNA binding protein (DNMT3B, DNMT3L and MBD2), 5-hydroxymethylcytosine converting enzyme (TET1), transcriptional activator-repressor complex (MED12L, HDAC9, SETBP1 and PRDM2), and several transcriptional factors (especially, homeobox and helix-loop-helix-type DNA binding molecules). Surprisingly, these include many leukemia-associated oncoproteins that are partners of disease-causing interchromosomal translocations. As epigenetic regulation is a crucial factor for establishment and maintenance of normal stem cells as well as CSC (Glinsky, 2008) , it can be hypothesized that these oncoproteins may have a pivotal role in the epigenetic signature of CSC in both hematopoietic and pulmonary endocrine tumors, and we further showed that downregulation of these molecules affected the colony formation activity and the expression of CSC markers. Thus, DEK may maintain the tumor-initiating activity of solid tumors, at least partly through modulation of these transcriptional regulators, suggesting that a common molecular pathway functions in the maintenance of both liquid and solid CSCs. It has been shown that DEK overexpression interferes with differentiation and expands the population of undifferentiated keratinocytes (Wise-Draper et al., 2009b) , supporting the contention that DEK also has a significant role in normal epithelial stem cell maintenance.
It remains unknown how much population of HGNEC is contributing to tumor-initiating in vivo. As DEK is widely expressed in primary HGNEC, an arising question is how DEK specifically regulates a set of genes in distinct cellular contexts, such as CSC. One possibility is that additional modification of DEK might determine its target specificity (Kappes et al., 2004; Scoumanne and Chen, 2007) . Another, but not exclusive, idea is that additional cooperation with other transcriptional factors or nucleosome/chromatin assembly factors may mark specific DEK binding or work cooperatively and induce characteristic transcriptional changes, as DEK has been shown to interact with several epigenetic modifiers (Hollenbach et al., 2002; Cleary et al., 2005; Cavella´n et al., 2006) . These hypotheses may also explain why broadly expressed DEK is associated with the tumor-initiating cells, a supposedly rare tumor subpopulation. That is, DEK overexpression may be required, but not sufficient, for establishment of tumorinitiating activity, and further modification or recruitment of associated factors might be necessary for its full oncogenic activity. We tested the latter possibility and focused on MLLT3 because it functions as a transcriptional activator itself in a similar way as the polycomb complex, which is known to be associated with CSC (Schuettengruber et al., 2007; Widschwendter et al., 2007) , and directly targets TAL1 and the Hox gene cluster (Collins et al., 2002; Pina et al., 2008) , which are also downregulated in DEK-silenced clones, and MLLT3 downregulation showed little effect on in vitro SCLC cell proliferation. We found that MLLT3 associates directly or indirectly with DEK and partially rescued colony-forming activity in DEK-silenced cells (Supplementary Figure 9) . MLLT3 translocation has a major role in leukemic stem cell development and is tethered to the potential CSC-related genes (Krivtsov et al., 2006) . Our preliminary study suggested that DEK indirectly associates with MLLT3, and the MLLT3-DEK nuclear complex might be recruited to the genes regulating lung tumor-initiating activity. Identification of the molecular mechanism underlying CSC maintenance is critical for devising new CSC-targeting therapies in lung cancer and further characterization of the specific nuclear DEK complex in CSC will be significant.
In conclusion, our study has proposed that HGNEC can be genetically classified and identification of novel molecular signatures should be valuable for the molecular diagnosis and individualized therapy of this malignant tumor. Our results also suggested that DEK has a direct role in determining the malignant features and tumor-initiating activity of HGNEC and could be a potential biomarker for assessment of prognosis and an attractive target of extensive therapeutic application including elimination of CSC population.
Materials and methods
Details of the experimental procedures are described in the Supplementary Material.
Clinical samples, DNA extraction and immunohistochemistry Surgical specimens from 101 Japanese patients with lung neuroendocrine tumor (11 TCs, 2 ACs, 25 SCLCs and 63 LCNECs), who were diagnosed and underwent surgery at the National Cancer Center Hospital, Tokyo, Japan, between March 1982 and January 2004 were examined. Clinicopathological data of the analyzed cases are shown in the Supplementary Table 4 . Only cases with a consensus histological diagnosis agreed by the central board of pathologists were analyzed (Asamura et al., 2006) . Fragments of tumor were fixed with 100% methanol and embedded in paraffin. To obtain pure tumor DNA from 49 cases for array CGH analysis, laser-capture microdissection using an LM200 (MDS Analytical Technologies, Toronto, Canada) and the wholegenome PCR method were conducted. Immunohistochemistry was performed as previously described . This study protocol for clinical samples was approved by the institutional review board of the National Cancer Center.
Array CGH analysis
For array CGH analysis, a custom-made focused CGH array, consisting of 800 duplicated BAC clones corresponding to various chromosomal loci that are altered in various human cancers, was used (Sonoda et al., 2004) . Array CGH data of 23 HGNEC samples (8 SCLC and 15 LCNEC cases) have been previously reported (Peng et al., 2005) . Sixteen-bit fluorescence intensity TIF images were obtained using a scanner (FLA8000, Fuji Film, Tokyo, Japan) and analyzed using GenePix Pro 5.0 (Axon Instruments Inc., Foster City, CA, USA).
Cell biological and biochemical experiments
Cell proliferation, cell migration assay, soft agar colony assay and immunofluorescent analysis were performed as described previously (Shibata et al., 2003 (Shibata et al., , 2008 . For cell sorting analysis, cells were stained with propidium iodide (Sigma-Aldrich, St Louis, MO, USA) for cell cycle analysis, or anti-CD133 antibody (CD133/1-PE, Miltenyi Biotec, Bergisch Gladbach, Germany) for lung cancer stem cell analysis. Fluorescence-activated cell sorting analysis was performed using fluorescence-activated cell sorting Calibur (BD Biosciences, San Jose, CA, USA) as the manufacture's protocol. For protein extraction, we used a slightly modified buffer (10 mM Tris-HCl (pH7.5), 175 mM NaCl, 5 mM EDTA, 0.5% Triton-X, 0.5% NP-40 with a proteinase inhibitor cocktail (Roche, Mannheim, Germany), and the procedures of immunoprecipitation and immunoblotting were preformed as described (Shibata et al., 2008) .
For assessment of in vivo tumorigenicity, 1 Â 10 6 cells were subcutaneously transplanted into the trunks of nude mice. The mice were kept at the Animal Care and Use Facilities at the National Cancer Center under specific pathogen-free conditions and all experiments were approved by the Institutional Animal Care and Ethics Committee.
Gene expression analysis and quantitative PCR
In all, 10mg of total RNA was reverse-transcribed by MMLV reverse transcriptase, and a Cy3-labeled cRNA probe was synthesized using T7 RNA polymerase. Probes were hybridized with a microarray containing 41 000 long oligonucleotides covering the whole human genome (Whole Human Genome Oligo Microarray, G4112F, Agilent Technologies, Santa Clara, CA, USA). After washing, the microarray was scanned by the DNA microarray scanner (Agilent Technologies). Quantitative genomic PCR and reverse transcriptase PCR was performed in triplicate and evaluated using universal probes for each amplicon and the Light-cycler system (Roche). Primers designed by ProbeFinder (Version 2.45, Roche) and used in this study are shown in Supplementary Table 3 . The relative expression of each gene was determined by comparison with that of glyceraldehyde 3-phosphate dehydrogenase.
Statistics
Array CGH and microarray raw-data analysis was first conducted using the Gene Spring software package (Agilent technologies). Two-dimensional hierarchical clustering analysis of the samples and signal ratios was performed using the Impressionist (Gene Data, Basel, Switzerland) and GeneMaths (Applied Maths, Sint-Martens-Latem, Belgium) software programs, as described previously Katoh et al., 2007) . As we hypothesized that array CGH data includes the genetic heterogeneity of cancer cells that frequently occurs in primary tumor, we took the strategy for discovering prognostic BAC clones as follows: we directly used normalized ratio data for assessing prognostic BAC clones in the first set of samples, and then validate the results by an independent immunohistochemical analysis of the second sample set. We used the Significance Analysis of Microarrays software package (SAM; http://www-stat.stanford.edu/Btibs/SAM/ index.html) to select prognostic BAC clones and to identify genes differentially expressed between control and DEKsilenced clones. After 100 rounds of permutation test, an adjusted P-value and a false discovery rate were estimated. The Kaplan-Meier method was used to estimate the probability of disease-free survival.
